Preferred Label : Anti-ILT2/Anti-ILT4 Monoclonal Antibody NGM707;
NCIt synonyms : Anti-ILT2/ILT4 Monoclonal Antibody NGM707; ILT2/ILT4 Dual Antagonist Monoclonal Antibody NGM707;
NCIt definition : A humanized, dual antagonist monoclonal antibody directed against the inhibitory immune
checkpoint receptors immunoglobulin (Ig)-like transcript 2 (ILT2; leukocyte immunoglobulin-like
receptor subfamily B member 1; LILRB1; leukocyte immunoglobulin-like receptor 1; LIR1;
monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j) and ILT4 (LILRB2;
LIR2; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities.
Upon administration, anti-ILT2/anti-ILT4 monoclonal antibody NGM707 targets and binds
to both ILT2 and ILT4. This prevents the binding of ILT2 and ILT4 ligands, including
the major histocompatibility complex class I (MHC I) molecules human leukocyte antigen
(HLA)-A, HLA-B, HLA-C and HLA-G, to the ILT2 and ILT4 receptors and prevents ILT2-
and ILT4-mediated signaling. This inhibits ILT2- and ILT4-mediated immune suppression
and may activate both innate and adaptive immune responses, including natural killer
(NK) and CD8 T-cell tumor cell killing, and macrophage phagocytosis of tumor cells.
ILT2 and ILT4, expressed on myeloid cells in the tumor microenvironment (TME), are
upregulated in various cancer types and play an important role in tumor immune evasion.
ILT2 is also expressed on various innate and adaptive immune cells including NK cells,
B-cells and a subset of cytolytic T-cells.;
Molecule name : NGM-707; NGM 707;
NCI Metathesaurus CUI : CL1663657;
Origin ID : C180904;
UMLS CUI : C5556706;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
